Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Trial Profile

Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs Clostridium difficile vaccine (Primary)
  • Indications Clostridium difficile infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Cdiffense
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 06 Feb 2019 This study has been completed in United Kingdom.
    • 05 Feb 2018 Planned End Date changed from 1 Oct 2019 to 16 May 2019.
    • 05 Feb 2018 Planned primary completion date changed from 1 Oct 2019 to 16 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top